ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconIcon FacebookIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Nikkei Markets

Fosun Pharma To Buy Out Other Shareholders In Taiwan-Based Henlix Biotech

By Carrie Chen
Nikkei Markets
HONG KONG (Nov 02) -- Shanghai Fosun Pharmaceutical (Group), a company controlled by Chinese conglomerate Fosun International, said a unit has agreed to acquire the 69.25% stake it doesn't already own in Taiwan-based biopharmaceutical company Henlix Biotech for up to $98 million.

The company's unit Shanghai Henlius will buy out other corporate and individual shareholders and make Henlix a wholly-owned subsidiary, Fosun Pharma said in a filing to the Hong Kong stock exchange on Thursday.

The agreement is subject to approvals from authorities in Taiwan and China.

?
- By Carrie Chen; Carrie.Chen@NikkeiNewsrise.com; +852 39605153
- Edited By V.Phani Kumar
- Send Feedback to feedback@NikkeiNewsRise.com
- Copyright (c) 2017 Nikkei NewsRise Asia Pte Ltd.

Get unique insights on Asia, the most dynamic market in the world.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media